tradingkey.logo
搜索

Exact Sciences Corp

EXAS
添加自选
104.910USD
0.0000.00%
收盘 06/29, 16:00美东报价延迟15分钟
20.03B总市值
亏损市盈率 TTM

关于 Exact Sciences Corp 公司

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Exact Sciences Corp简介

公司代码EXAS
公司名称Exact Sciences Corp
上市日期Jan 30, 2001
CEOConroy (Kevin T)
员工数量6900
证券类型Ordinary Share
年结日Jan 30
公司地址5505 Endeavor Lane
城市MADISON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编53719
电话16082845700
网址https://www.exactsciences.com/
公司代码EXAS
上市日期Jan 30, 2001
CEOConroy (Kevin T)

Exact Sciences Corp公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Mr. D. Scott Coward
Mr. D. Scott Coward
Director
Director
--
--
Mr. Jacob (Jake) Orville
Mr. Jacob (Jake) Orville
Executive Vice President, General Manager - Screening
Executive Vice President, General Manager - Screening
--
--
Mr. Paul Clancy
Mr. Paul Clancy
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%

常见问题

Exact Sciences Corp的前五大股东是谁?

Exact Sciences Corp 的前五大股东如下:Mr. Kevin T. Conroy

有多少机构持有Exact Sciences Corp(EXAS)的股份?

截至2026Q1,共有1452家机构持有Exact Sciences Corp的股份,合计持有的股份价值约为147.12M,占公司总股份的77.07%。与2025Q4相比,机构持股有所增加,增幅为-48700001.00。

哪个业务部门对Exact Sciences Corp的收入贡献最大?

在2026Q1,Commercial业务部门对Exact Sciences Corp的收入贡献最大,创收1.52B,占总收入的46.79%。
KeyAI